BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Gliknik Inc. Adds Incyte Corporation (INCY) President & CEO Paul A. Friedman to its Board of Directors


2/25/2013 8:56:34 AM

BALTIMORE, Feb. 25, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company, today announced the appointment of Incyte Corporation President and Chief Executive Officer Paul A. Friedman, M.D., to its Board of Directors. Dr. Friedman, a seasoned pharmaceutical industry executive with strong experience in management of R&D and corporate functions, joins Gliknik's board as the company is continuing to advance its pipeline of drug candidates targeting various cancers and immune disorders.

"It's an honor for us to welcome Paul to the Gliknik Board of Directors," said Gliknik CEO David S. Block. "His deep experience in pharmaceutical research, development, commercialization, and business development and his unwavering commitment to excellence bring an important perspective to Gliknik as we seek to advance and to partner our pipeline of novel therapies."

Dr. Friedman joined Incyte in 2001 as Chief Executive Officer and a Director. A biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation, Incyte developed and commercialized Jakafi® (ruxolitinib) under Dr. Friedman and has a robust product pipeline. Previously, Dr. Friedman served as President of R&D for the DuPont Merck Pharmaceutical Company, President of DuPont Pharmaceuticals Research Laboratories, and Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman is also a director of Auxilium Pharmaceuticals, Inc.

"I welcome the opportunity to join the Gliknik Board of Directors and look forward to contributing to its goal of advancing and partnering the company's clinical immunomodulator and preclinical stradomer programs," said Dr. Friedman.

About Gliknik Inc.
Founded in 2007, Gliknik is a biopharmaceuticals company creating new therapies for patients with cancer and immune disorders. Gliknik expertise is in modulation of the immune system to fight disease. In addition to the stradomer program for autoimmune diseases, Gliknik also has commercial rights to two cancer immunomodulator drugs that are in multiple-dose clinical trials in patients with advanced head and neck cancer and in patients with advanced multiple myeloma. Learn more at www.gliknik.com.


SOURCE Gliknik Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->